Close Menu

NEW YORK – Daiichi Sankyo and AstraZeneca announced on Tuesday that the US Food and Drug Administration has accepted the supplemental biologics license application for trastuzumab deruxtecan (Enhertu) to treat patients with HER2-positive gastric cancer.

The FDA also granted priority review for trastuzumab deruxtecan for the treatment of patients with HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. The treatment also has received a breakthrough therapy designation and orphan drug designation for this indication.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.